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Abstract
Background: TMP21 is a member of the p24 cargo protein family, which is involved in protein transport between
the Golgi apparatus and ER. Alzheimer’s Disease (AD) is the most common neurodegenerative disorder leading to
dementia and deposition of amyloid b protein (Ab) is the pathological feature of AD pathogenesis. Knockdown of
TMP21 expression by siRNA causes a sharp increase in Ab production; however the underlying mechanism by
which TMP21 regulates Ab generation is unknown, and human TMP21 gene expression regulation has not yet
been studied.
Results: In this report we have cloned a 3.3-kb fragment upstream of the human TMP21 gene. The transcription
start site (TSS) of the human TMP21 gene was identified. A series of nested deletions of the 5’ flanking region of
the human TMP21 gene were subcloned into the pGL3-basic luciferase reporter plasmid. We identified the -120 to
+2 region as containing the minimal sequence necessary for TMP21 gene promoter activity. Gel shift assays
revealed that the human TMP21 gene promoter contains NFAT response elements. Expression of NFAT increased
TMP21 gene expression and inhibition of NFAT by siRNA reduced TMP21 gene expression.
Conclusion: NFAT plays a very important role in the regulation of human TMP21 gene expression. This study
demonstrates that the human TMP21 gene expression is transcriptionally regulated by NFAT signaling.
Background
Alzheimer’s disease is the most common neurodegen-
erative disorder leading to dementia. Deposition of amy-
loid b protein (Ab) in the brain is one of the hallmarks
of AD pathogenesis. Ab is generated from a larger b-
amyloid precursor protein (APP) by sequential cleavages
of b-secretase and g-secretase [1-4]. Beta-site APP cleav-
ing enzyme 1 (BACE1) is the b-secretase in vivo [5,6],
and g-secretase activity is catalyzed by a presenilin (PS)-
containing macromolecular complex [7]. This high
molecular weight complex also requires nicastrin (Nct)
[8], anterior pharynx-defective 1 (Aph-1) [9-11], and
presenilin enhancer 2 (Pen-2) [9,10] for its enzymatic
activity [7,11-13]. CD147 was also found to closely
associate with the g-secretase complex [14]. Despite
robust expression of the APP gene resulting in a high
level of APP protein in vivo, Ab production through the
amyloidogenic pathway of APP processing is a rare
occurrence under normal conditions [15,16].
Missense mutations in PS1 and PS2 are a major cause
of early-onset familial AD (FAD). PS mutant forms have
been shown to increase g-secretase activity, resulting in
elevated Ab42 production [17-19]. In addition to its
pathogenic g-secretase activity, the PS complex can
cleave Notch [20,21] at a separate ε-cleavage site which
may be involved in learning and memory. Intramembra-
nous cleavage of Notch to release the Notch intracellu-
lar domain (NICD) is inhibited in PS1-deficient cells
[8,20,22-24]. In addition to APP and Notch, the sub-
strates for g-secretase include Jagged, Delta, E-cadherin,
ErbB-4, Nectin-1a, CD44 and LRP. The ε- and g-secre-
tase activities of the presenilin complex seem to be inde-
pendently regulated, as certain g-secretase inhibitors can
affect APP cleavage without affecting Notch cleavage,
and presenilin mutations can increase Ab-42 production
while decreasing Notch cleavage [25,26].
Human TMP21, a member of the p24 protein family,
is a type I transmembrane protein with a large luminal
domain [27]. It is ubiquitously transcribed with higher
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protein levels in the pancreas and intestines. The cyto-
plasmic tails of p24 family interact with coatomer, a
major component of coat protein complex I (COP-I), to
facilitate transport between the ER and Golgi [28-30].
TMP21 cycles through the early secretory pathway
between the intermediate and cis-Golgi compartments
[31-33], and is necessary for proper organization of the
Golgi apparatus [34,35]. TMP21 also plays an essential
and non-redundant role in the earliest stages of mam-
malian development [36]. Recently, TMP21 was identi-
fied as a new member of the PS-associated complex
[37]. Our recent study showed that TMP21 is ubiquiti-
nated and that degradation of TMP21, as with the other
PS-associated g-secretase complex members, is mediated
by the ubiquitin-proteasome pathway [38]. Interestingly,
TMP21 has been shown to regulate Ab generation but
not Notch processing, suggesting that TMP21 selectively
regulates g-secretase, but not ε-secretase, activity [37].
Gene expression requires tightly controlled gene tran-
scription regulated by interaction between cis-acting ele-
ments in the promoter region and transcription factors.
It is well known that the nuclear factor of activated T
cells (NFAT)/calcineurin family play a central role in
inducible gene transcription in various signaling path-
ways, regulating cell differentiation, development, adap-
tation, immune system response, inflammatory,
adipocyte metabolism, and lipolysis, as well as carcino-
genesis [39-42]. There are a few NFAT family isoforms
in different tissue. NFAT localization in the nucleus is
dependent on the import-export balance between the
activity of Ca2+/calmodulin-dependent phosphatase, cal-
cinurin, and the activity of serine/threonine kinase [43].
NFAT signaling is pivotal during embryogenesis for car-
diovascular development [44], and affects the cytokine
and immunoregulatory gene transcriptional activator in
T cells, as well as various other physiological activities
beyond the immune system. It is also involved in regula-
tion of cell growth, differentiation, and cell cycle pro-
gression in diverse cell types after birth [45,46].
NFAT proteins are phosphorylated and constitutively
expressed in resting cells [47,48]. Phosphorylated NFAT
normally resides in the cytoplasm and has low affinity
for DNA binding [49,50]. The anastomosis of cell sur-
face receptors to the calcium-signaling pathway activates
phospholipase C-g, causing phosphatidylinosito-4,5-
biphosphate, a plasma membrane component, to be
hydrolyzed, producing cytosolic inosito-1,4,5-trispho-
sphate (IP3) and membrane-bound diacylglycerol. IP3
induces calcium release from the ER, stimulating cal-
cium-activated calcium channels on the plasma mem-
brane to open, which then maintains the increased level
of intracellular calcium. The ratio of calcium/calmodulin
triggers Ser/Thr-phosphatase calcineurin (CaN), which
can dephosphorylate NFAT [51]. Dephosphorylated
NFAT protein can be translocated to the nucleus and
has a high affinity for DNA binding, inducing NFAT-
dependent gene transcription [48,52-54]. The calci-
neurin inhibitors CsA or FK506 can block NFAT activa-
tion. The NFAT binding site in the promoter of target
genes has a 9 bp consensus sequence (A/T)GGAAA(A/
N)(A/T/C)N [47]. The calcineurin inhibitors CsA or
FK506 can block NFAT activation. The mechanism
underlying the transcriptional regulation of human
TMP21 and its role in neuropsychiatric disorder patho-
genesis is unknown. In order to study the molecular
mechanism of human TMP21 gene transcription regula-
tion, we cloned and functionally characterized the
human TMP21 gene promoter. We found that tran-
scription factor NFAT plays a pivotal role in regulation
of TMP21 gene transcription.
Results
Cloning the human TMP21 gene promoter and mapping
its transcription start site
Human TMP21 is ubiquitously transcribed with higher
protein levels in the pancreas and intestines. The
human TMP21 gene is located on chromosome 14q24.3
and spans 45,179 base pairs. It has five exons and
encodes for a 21-kD protein of 219 amino acids (Figure
1A). To examine its transcriptional regulation, 3333 bp
of the 5’ flanking region of the human TMP21 gene was
cloned from human genomic DNA. To determine the
transcription start site of TMP21, RNA Ligase Mediated
Rapid Amplification of cDNA Ends (RLM-RACE) assay
was performed. A 182 bp major cDNA product from
the nested-PCR was amplified and cloned into pcDNA4
vector (Figure 1B). DNA sequencing indicates that the
major transcription start site is located at 43 bp
upstream of the translation start site ATG. This tran-
scription initiation site is designated as +1 and begins
with cytosine (Figure 1C). Sequence analysis and a com-
puter-based transcription factor binding site search
(MatInspector 2.2, Genomartrix, Oakland, CA, USA)
reveals that the human TMP21 gene has a complex
transcriptional unit. The human TMP21 gene promoter
lacks typical CAAT and TATA boxes and contains sev-
eral putative regulatory elements, such as AP1, SP1,
CREB, NFAT, HIF-1, GATA as well as STAT (Figure
1D).
Functional characterization of the TMP21 promoter
To determine whether the 3.3-kb fragment from -3108
to +225 bp of the TMP21 5’ flanking region contains
the human TMP21 promoter, the pTMP-3108+225 plas-
mid was constructed to contain this fragment upstream
of a luciferase reporter gene in the promoterless plasmid
pGL3-basic. The pGL3-basic vector lacks a eukaryotic
promoter and enhancer sequences upstream of the
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reporter luciferase gene. Expression of luciferase in cells
transfected with this plasmid depends on a functional
promoter upstream of the luciferase gene. Plasmid DNA
was transfected into HEK293 cells and luciferase activity
was measured with a luminometer to determine
promoter activity. Promoterless empty vector pGL3-
basic was used as negative control and CMV promoter-
luciferase construct pGL3-promoter was transfected as a
positive control. Compared with cells transfected with
pGL3-basic or pGL3-promoter controls, cells transfected
Figure 1 Sequence features of the human TMP21 gene promoter and identification of the transcription start site. (A) The genomic
organization of human TMP21 gene on Chromosome 14q24.3. E represents exon. ATG is the translation start codon and TAA the stop codon.
(B) RLM-RACE experiment was performed to map the TMP21 transcription start site. Neuronal RNA was extracted by TRI-Reagent from SH-SY5Y
cells. Total RNA was treated with Calf Intestine Alkaline Phosphatase to remove free 5’-phosphates and the RNA was then treated with Tobacco
Acid Pyrophosphatase (TAP) to remove the cap structure from full-length mRNA, leaving a 5’-monophosphate. A 45 base RNA Adapter
oligonucleotide was ligated to the RNA population using T4 RNA ligase. A random-primed reverse transcription reaction and nested PCR then
amplified the 5’ end of a specific transcript. The product was analyzed on a 1.5% agarose gel. (C) The PCR product was cloned into pcDNA4-
mycHis at BamHI and XhoI sites. DNA sequencing was performed to identify the insert sequence. The first base pair after the adapter was the
transcription start site (TSS). The arrow indicates the TSS. (D) The nucleotide sequence of the human TMP21 gene promoter. A 3333-bp fragment
of the 5’ flanking region of the human TMP21 gene was isolated from a human BAC genomic clone and sequenced by the primer walking
strategy. The cytosine +1 represents the TSS mapped by RLM-RACE. The putative transcription factor binding sites are underlined in bold face.
Amino acid codons were boxed in boldface. Genbank™accession number is JF694939.
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with pTMP-3108+225 had significantly higher luciferase
activity (57.03 ±6.83 RLU, P < 0.001) (Figure 2B). This
result indicated that the 3.3 kb 5’ flanking region of the
TMP21 gene contains the functional promoter for
human TMP21 gene transcription.
To functionally analyze the TMP21 promoter and
identify the minimal promoter region needed for
TMP21 gene expression, a series of deletions of the 5’
flanking fragments of TMP21 were subcloned into
pGL3-basic (Figure 2A). Deletion of 1047 bp upstream
from pTMP-3018+225 had no significant effect on the
luciferase activity of cells transfected with plasmid
pTMP-2061+225 (66.02 ± 11.51RLU) (P > 0.05 relative
to pTMP3018+225). However, further deletions (pTMP-
1260+33) had significantly higher promoter activity
(94.70 ± 2.54 RLU, P < 0.005), suggesting the deleted
region might contain inhibitory cis-acting elements.
Inserting the -1260+33 fragment in the reverse direction
upstream of luciferase reporter gene (plasmid pTMP
+33-1260) resulted in little luciferase expression. These
data further supported that the 5’ flanking region con-
tains the functional human TMP21 gene promoter.
To identify the minimal region containing TMP21 pro-
moter activity, further deletion plasmids were con-
structed. Plasmid pTMP-596+33, pTMP-225+33 and
pTMP-120+33 had luciferase activity at 49.78 ± 1.16,
43.51 ± 0.41, and 58.16 ± 3.11 RLU, respectively (Figure
2B). A 31 bp deletion from the 3’ end of the -120 to +33
bp fragment significantly reduced the luciferase activity
from 58.16 ± 3.11 RLU in pTMP-120+33 to 37.07 ± 1.85
RLU in pTMP-120+2 (P < 0.005). However, a further 58
bp 3’ deletion resulted in little luciferase activity in
pTMP-120-57 (P < 0.001) (Figure 2B). The results indi-
cate that the 5’ flanking region from -120 to +2 bp, con-
taining the transcription initiation site, is the minimal
promoter region necessary for basal transcription of
TMP21, and the fragment from -120 to -57, lacking the
transcription start site, has no promoter activation ability.
The human TMP21 gene promoter contains NFAT cis-
acting response elements
NFAT signaling regulates gene transcription by translo-
cation of activated dephosphorylated NFAT into nucleus
to bind an NFAT response element in the promoter of
target genes. The NFAT binding element contains a 9
bp consensus sequence (A/T)GGAAA(A/N)(A/T/C)N
[49]. Sequence analysis indicates that there are eight
putative NFAT binding sites in the 3.1 kb promoter
region of the human TMP21 gene (Figure 1B). To inves-
tigate whether those putative NFAT elements are func-
tional NFAT binding sites, gel shift assays were
performed. A 12-bp consensus double-stranded NFAT
oligonucleotide probe was synthesized and end labeled
with IRDye-680 (Li-COR, Biosciences). A shifted pro-
tein-DNA complex band was detected after incubating
the labeled NFAT probe with HEK293 nuclear extract
(Figure 3, lane2 of panel ABCD). The intensity of the
shifted band was significantly reduced by adding 10 fold
excess of unlabeled NFAT consensus competition oligo-
nucleotides (Wt-NFAT), and the band was almost
entirely abolished by applying a 100-fold excess of unla-
beled NFAT consensus oligonucleotides (Figure 3, lane
3,4 of panel ABCD). Applying a 10-fold excess of
mutant NFAT consensus oligonucleotides (Mt-NFAT),
which contain a binding site mutation, had no compet-
ing effect on the NFAT protein-DNA binding complex
shifted band (Figure 3, Lane 5 of Panel ABCD). 100-fold
Mt-NFAT oligos could show some non-specific compe-
tition (Lane 6). Only a 10-fold and 100-fold excess of
the 7th putative NFAT response element (TMP21-
NFAT-7) could markedly reduce the intensity and com-
pletely abolish the signal of the shifted bands, respec-
tively, when compared to preincubation of the 8
unlabeled TMP21-NFAT probes with HEK293 nuclear
extract, (Figure 3D). This result indicated that a NFAT
binding site is located at -502 bp to -476 bp of the
human TMP21 promoter region.
To investigate the interaction between transcription
factor NFAT and the human TMP21 promoter in
HEK293 (Figure 4A) and SH-SY5Y (Figure 4B) cells,
chromatin immunoprecipitation (ChIP) assay was per-
formed. As positive control, TMP21 promoter and
b-actin DNA fragment were amplified from the sheared
chromatin samples (lane 2). Only TMP21 promoter
fragment can be amplified from the sheared chromatin
Figure 2 Deletion analysis of the human TMP21 gene
promoter. (A) Schematic diagram of the TMP21 promoter
constructs consisting of the 5’ flanking region with serial deletions
cloned into the pGL3-basic vector. Arrow shows the direction of
transcription. The numbers represent the end points of each
construct. The deletion plasmids were confirmed by sequencing
and restriction enzyme digestion. (B) The plasmid constructs were
co-transfected with pRLuc into HEK293 and SH-SY5Y cells by
Lipofectamine 2000R. After 48 hour transfections the cells were
harvested and luciferase activity was measured with a luminometer
and expressed in Relative Luciferase Units (RLU). Renilla luciferase
activity was used to normalize for transfection efficiency. The values
represent means ± SEM. *, P < 0.001 by analysis of variance with
the post hoc Newman-Keuls test.
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sample immunoprecipitated by NFAT antibody (lane 4,
but not from the chromatin sample incubating with
non-NFAT antibody solution control (lane 3). No b-
actin DNA fragment was pulled down from those two
samples either. The results clearly showed that NFAT
proteins are associated with TMP21 promoter region in
both HEK293 and SH-SY5Y cells.
NFAT expression increases and pyrrolidine
dithiocarbamates (PDTC) decreases human TMP21
promoter activity
To examine the role of NFAT signaling in the regula-
tion of human TMP21 transcription and expression, we
first examined TMP21 promoter activity in cells overex-
pressing NFAT protein. Either pTMP-1260+33 or pGL3
promoter were co-transfected with NFAT expression
plasmid or empty vector into HEK293 or N2a cells.
pRLuc was also transfected for transfection efficiency
normalization. The cells were harvested with lysis buffer
48 later after transfection and luciferase activity was
measured. The luciferase activity of pTMP-1260+33
was significantly increased by 2.40-fold in cells co-
transfected with NFAT expression plasmid (P < 0.001)
(Figure 5A). To further demonstrate that NFAT site in
TMP21 promoter mediates NFAT’s effect on TMP21
expression, pTMP-120+33 was also co-transfected with
NFAT expression plasmid or empty vector. pTMP-120
+33 promoter plasmid lacks NFAT binding site and our
results showed that NFAT overexpression had no signif-
icant effect on its luciferase activity (P > 0.05) (Figure
5A). These results indicate that human TMP21 gene
promoter activity can be significantly up-regulated by
NFAT over-expression via its NFAT response element.
Pyrrolidine dithiocarbamates (PDTC) is an antioxidant
compound which strongly inhibits NF-B and activates
AP-1 signaling. PDTC was also shown to have a strong
inhibitory effect on NFAT signaling and its downstream
gene transcription [55]. To further examine NFAT’s
effect on TMP21 transcription, HEK293 and N2a were
transfected with plasmid pTMP-596+33. The cells were
then treated with 100 μM PDTC for varying times and
doses of PDTC for 24 hours. Cell lysates were assayed for
luciferase activity. PDTC treatment significantly reduced
TMP21 promoter activity. Addition of 50, 100, 200 uM
of PDTC for 16 hours decreased promoter activity to
84.99 ± 4.72%, 26.25 ± 8.11% and 15.15 ± 2.48%, respec-
tively (P < 0.001) (Figure 5C). 100 μM PDTC treatment
for 1, 4, 16 and 20 hours reduced TMP21 promoter activ-
ity to 68.32 ± 8.84%, 60.67 ± 18.23% and 11.63 ± 2.01%
and 6.80 ± 0.06%, respectively (P < 0.001) (Figure 5D).
These data demonstrated that NFAT inhibitor PDTC can
inhibit human TMP21 promoter activation in a time-
and dosage-dependent manner.
Regulation of TMP21 expression by NFAT activity
To examine the effect of NFAT on endogenous TMP21
mRNA and protein levels, HEK293 and SH-SY5Y cells
Figure 3 Gel mobility shift assay for the TMP21 gene
promoter. Gel shift assays were performed as described in the
Material and Methods. Double stranded NFAT oligonucleotide
probes labeled wuth IRDye-680 were applied. Lane 1 is labeled
probe alone without nuclear extract. Incubation with nuclear
extracts retarded the migration rate of the labeled probe, forming a
new shifted DNA-protein complex band (lane 2). Competition assays
were performed by further adding different concentrations of molar
excess of unlabeled competition oligonucleotides, consensus NFAT
(lane 3, 4), binding sequence mutant NFAT (lane 5, 6) and TMP21
NFAT elements (lane 7, 8, 9, 10).
Figure 4 ChIP assay to show that NFAT proteins are associated
with human TMP21 promoter. ChIP assay was performed as
described in the Material and Methods. The chromatin was isolated
HEK293 (A) or SH-SY5Y cells (B), and then sheared from the cells
treated with cross-link reagent formaldehyde. For isolation of NFAT
binding complex, the chromatin solution was incubated with NFAT
antibody (Santa Cruz). PCR amplifications were performed using
TMP21 promoter-specific primers, with samples from the sheared
chromatin alone (lane 2), non-NFAT antibody control (lane 3) and
NFAT-immunoprecipitating chromatin sample (lane 4). b-actin was
used as internal control.
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were transfected with NFAT expression plasmid and
NFAT-specific siRNA. The samples were analyzed by
semi-quantitative RT-PCR and Western blot with b-
actin levels as the internal control. RT-PCR showed that
NFAT expression significantly increased endogenous
TMP21 mRNA levels (151.73 ± 1.36%, P < 0.001), while
knockdown of NFAT expression by siRNA markedly
reduced endogenous TMP21mRNA levels (58.94 ±
0.63%, P < 0.001) in HEK293 cells (Figure 6A and 6C).
Similar results were also observed in SH-SY5Y cells:
NFAT overexpression increased TMP21 mRNA levels to
128.00 ± 0.66% and NFAT siRNA reduced the levels to
30.98 ± 0.34% (P < 0.001 relative to control) (Figure 6B
and 6C). Consistent with the transcription data, Western
blot analysis showed that TMP21 protein levels were
significantly increased by NFAT expression in HEK293
cells (155.78 ± 1.075%) (Figure 6D and 6F) and SH-
SY5Y cells (141.62 ± 1.64%) (Figure 6E and 6F), and
knockdown of NFAT expression markedly decreased
TMP21 protein levels in HEK293 (49.29 ± 0.64%) (Fig-
ure 6D) and SH-SY5Y cells (64.83 ± 0.96%) (Figure 6E),
respectively (P < 0.001 relative to control) (Figure 6F).
Taken together, these results clearly demonstrate that
NFAT signaling regulates human TMP21 gene
expression.
Discussion
Beta-secretase cleavage of APP by BACE1 produces APP
C-terminal fragment C99, which can be cleaved by the
g-secretase complex to form Ab and subsequently aggre-
gate to form classic AD plaques. The g-secretase com-
plex requires PS1, Nct-1, Aph-1, and Pen-2 for its
enzymatic activity [7]. Recently, TMP21 was identified
as a member of the g-secretase complex [37]. Knock-
down of TMP21 with siRNA increased g-secretase activ-
ity and Ab production without altering the relative
amounts of g-secretase complex components or APP
substrate, suggesting that TMP21 is a selective regulator
of g-secretase [37]. TMP21 is a type I transmembrane
protein involved in ER/Golgi transport [27]. Interest-
ingly, the cDNA sequence of TMP21 is similar to cDNA
clone S31iii125, which was identified within the AD3
Figure 5 Regulation of TMP21 promoter activity by NFAT and
PDTC. Transcriptional activation of the TMP21 promoter is
potentiated by NFAT. Empty vector and TMP21 promoter plasmid
pTMP-1260+33 or pTMP-120+33 were cotransfected with NFAT
expression plasmid pHA-NFAT1 into HEK293 cells (A) or N2a cells
(B). Overexpression of NFAT significantly increased pTMP21-1260+33
or promoter activity and had no effect on pTMP-120+33 or control
plasmid in both HEK293 and N2a cells. n = 4, * p < 0.0001. (C, D)
Inhibition of TMP21 promoter activity by PDTC. TMP21 promoter
construct pTMP21-1260+33 and pRluc were cotransfected into
HEK293 and N2a cells. After 24 h cells were treated with varying
dosages of PDTC for 16 hours (C) or at 100uM for varying times (D).
Cells were harvested at the same time for luciferase assay. Renilla
luciferase activity was used to normalize for transfection efficiency.
The values represent means ± SEM relative to control promoter
activity. *, P < 0.001 relative to control by ANOVA with the post hoc
Newman-Keuls test.
Figure 6 NFAT facilitates TMP21 gene expression at both the
mRNA and protein level. HEK293 (A) and SH-SY5Y (B) cells were
transfected with NFAT expression plasmid or NFAT siRNA (sc-29412,
Santa Cruz Biotechnology, Inc.). Total RNA was extracted. Semi
quantitative RT-PCR was performed to detect the mRNA levels of
TMP21 and b-actin. Specific TMP21 and b-actin coding sequence
primers were used to amplify the TMP21 and b-actin cDNA, as
described in Materials and Methods. The RT-PCR products were
analyzed on 1% agarose gels. b-actin was used as internal control.
(C) The ratio of TMP21 to b-Actin mRNA was quantitated by Kodak
Image Analysis. Shown is the Mean+S.E.M., and n = 4. *p < 0.001
relative to controls by ANOVA with post-hoc Newmann-Keuls test.
(D and E) Western blot assay was then performed to analyze cell
lysates from NFAT-transfected cells and NFAT siRNA on 16% Tris-
Glycine gel. TMP21 protein was detected using rabbit anti-mouse
anti-TMP21 ployclonal antibody T21 and b-actin was used as an
internal protein control. Overexpression of NFAT increased TMP21
protein generation and NFAT siRNA decreased the protein levels in
HEK293 (D) and SH-SY5Y (E) cells. (F) Quantitative analysis of the
generation of TMP21. Values are Means ± S.E.M. and n = 4. The
protein levels are expressed as a percentage of the levels in control
cells. * p < 0.001 relative to controls by ANOVA with post-hoc
Newmann-Keuls test.
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locus on chromosome 14q24.3, which is associated with
aggressive, early-onset AD [56]. This, coupled with its
role as a selective regulator of g-secretase activity,
strongly suggests that TMP21 may play an as of yet
undetermined role in AD pathogenesis.
The TMP21 gene is prolifically expressed in the pan-
creas, nervous system, and digestive tract. To define the
molecular mechanism underlying human TMP21 gene
transcription and expression, we cloned 3.3 kb of the 5’
flanking region of the human TMP21 gene. We used 5’-
RACE to map the major transcription start site of
TMP21 at 43 bp upstream of the first ATG translation
codon. The promoter sequence does not contain TATA
or CATA boxes, typical features of most type II eukar-
yotic gene promoters. The promoter also does not have
high GC content, such as in APP and BACE1 gene pro-
moters [57], and does not resemble many housekeeping
gene promoters [58]. Sequence analysis suggested sev-
eral putative regulatory elements of the TMP21 promo-
ter, including NFAT, HIF, CREB, YY1F, AP1 and STAT.
A series of nested deletions of the 5’ flanking region of
the TMP21 promoter were subcloned into pGL3-Basic,
a luciferase reporter plasmid vector, and the luciferase
activity of TMP21 fragment was assayed. Our study
showed that the 5’ flanking region from -120 to +2 bp
contains the minimal promoter region necessary for
basal transcription of the human TMP21 gene. Gel shift
assays confirmed that a NFAT binding site is located at
-502 bp to -476 bp of the human TMP21 promoter
region. Furthermore, our results showed that human
TMP21 promoter activity can increase with co-expres-
sion of exogenous NFAT, and decrease after inhibition
of NFAT by PDTC. Finally we showed that overexpres-
sion of NFAT could increase endogenous TMP21
mRNA and protein levels, while knockdown decreased
them. These results clearly demonstrate that human
TMP21 gene expression is regulated by NFAT signaling
via its effect on a functional NFAT response element in
the human TMP21 gene promoter region. Our study
indicates that NFAT regulates TMP21 gene expression
at the transcription level and the human TMP21 gene is
one of the downstream target genes of NFAT signaling
pathway.
Abnormal regulation of gene transcription has been
implicated in the AD pathogenesis and pancreas endo-
crine function [16,59]. One of the pharmaceutical strate-
gies in AD therapy is to reduce Ab production. TMP21
protein is a new member of p24 cargo proteins and
plays an important role in Ab production in AD patho-
genesis. It was reported that reduction of TMP21 can
significantly increase Ab production [38]. Our study
provides new insights on the molecular mechanism
underlying transcriptional regulation of the human
TMP21 gene and we found that NFAT plays an
important role in the regulation of TMP21 gene expres-
sion both in neuronal and non-neuronal cells. Future
research will determine additional cis-acting elements in
the TMP21 promoter responsible for its neuronal and
pancreatic tissue-specific expression pattern, and how
dysregulation of TMP21 expression plays a role in the
pathogenesis of neuronal-endocrine disorders.
Conclusion
In this report we have cloned a 3.3-kb fragment upstream
of the human TMP21 gene. The transcription start site
(TSS) of the human TMP21 gene was identified. A series
of nested deletions of the 5’ flanking region of the human
TMP21 gene were subcloned into the pGL3-basic lucifer-
ase reporter plasmid. We identified the -120 to +2 region
as containing the minimal sequence necessary for
TMP21 gene promoter activity. Gel shift assays revealed
that the human TMP21 gene promoter contains NFAT
response elements. Expression of NFAT increased
TMP21 gene expression and inhibition of NFAT by
siRNA reduced TMP21 gene expression. These results
demonstrated that NFAT plays a very important role in
the regulation of human TMP21 gene expression.
Methods
Cloning of TMP21 promoter and construction of chimeric
luciferase reporter plasmids
The 5’-flanking region of the human TMP21 gene was
amplified by PCR from human BAC DNA NM_006827
gDNA-74712811-74722811R. The primers were
designed with restriction enzymes sites compatible with
the multi-cloning site of vector pGL3-basic (Promega).
Various 5’ flanking regions of TMP21 were cloned
upstream of the luciferase reporter gene in pGL3-basic.
The fragment of TMP21 was constructed from -3108 bp
upstream to +225 bp downstream of transcription start
site. The primers were used for deletion promoter con-
structs: forward, -3108: 5’-ccggtaccaaggtcaggatgttcaagac-
cagc, -2061: 5’-cgcgagctcctttaacagtataattatttggcctc, -1260:
5’-ccgctcgagttcaagcaattctctgcctc, -596: 5’-gctatgggacat-
gaaccggatgtc-3’, and -120: 5’- ccgctagccctatcctttcttccc;
reverse, -2061: 5’-cgcgagctcgaggccaaataattatactgttaaag,
-1159 5’-gaaaccccgtctctactaaaaatac, -561: 5’- cccaagc-
ttgttttaggggtcacctgatg, -148: 5’- gttaaagaagctttaatagaatac-
tattgc, -57: 5’-ccctcgag tggagactggcatgtagag, -38: 5’-
cccaagctttgatgccgtccgcgcc, -23: 5’- ccctcgagctcacctct-
gaccttc, 2: 5’-cccaagcttccggaaccggggggac, -10: 5’-
ccctcgagggacccacgtgactcac, and 33: 5’- ccctcgagactcgtt-
caccaccg. In order to construct the longest promoter
fragment of TMP21, -2061 Kpn I 5’-cgcgagctcctttaacag-
tataattatttggcctc and 225: 5’- ggtcggagatctcgtacgcgccag
were used to amplify -2061 to +225 bp region of
TMP21 promoter gene using BAC DNA. The fragment
was cloned into PGL3 basic at Kpn I and Bgl II to
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generate pTMP21-B, and then the fragment -3108 to
-2061 was inserted in pTMP21-B at Kpn I to construct
pTMP21-A containing the fragment of -3108 to +225
bp of TMP21 gene.
Cell culture, transfection and luciferase assay
HEK293 cells, SH-SY5Y and N2a cells were cultured in
Dulbecco’s modified Eagle’s medium containing 1 mM
sodium pyruvate, 10% fetal bovine serum, 2 mM of L-
glutamine and 50 units of penicillin and 50 ug of strep-
tomycin (Invitrogen, Carlsbad, CA USA). All cells were
cultured in an incubator at 37°C containing 5% CO2.
Cells were seeded in 24-well plats 24 hours before trans-
fection and grown to near 70% confluence by the day of
transfection. Cells were transfected with 0.5 ug plasmid
DNA per well using 1 μL Lipofectamine 2000 (Invitro-
gen). The Renilla (sea pansy) luciferase vector pRluc was
cotransfected to normalize for the transfection efficiency
of various luciferase reporter constructs. Cells were har-
vested at 48 hour after transfection and lysed in 50 μL
1× passive lysis buffer (Promega) per well. Firefly lucifer-
ase activities and Renilla luciferase activities were
assayed using the Dual-luciferase reporter assay system
(Promega). The firefly luciferase activity was normalized
according to Renilla luciferase activity and expressed as
relative luciferase units to reflect the promoter activity.
Plasmid HA-NFAT1 expresses HA-tagged murine
NFAT1 in pcDNA4 [60].
RNA Ligase Mediated Rapid Amplification of cDNA Ends
(RLM-RACE) of TMP21 gene
Total RNA was extracted from SH-SY5Y cells with TRI
reagent following the manufacturer’s protocol (Sigma, St
Louis, MO, USA). RLM-RACE was performed according
to the Instruction Manual: Poly (A) selected RNA is trea-
ted with Calf Intestine Alkaline Phosphatase (CIP) to
remove free 5’-phosphates from molecules. The RNA is
then treated with Tobacco Acid Pyrophosphatase (TAP)
to remove the cap structure from full-length mRNA, leav-
ing a 5’-monophosphate. A 45 base RNA Adapter oligonu-
cleotide was ligated to the RNA samples using T4 RNA
ligase. A random-primed reverse transcription reaction
and nested PCR then amplifies the 5’ end of a TMP21
transcript. The outer and inner primers, which were used
in nested PCR, were 5’-ggtcggagatctcgtacgcgccag and 5’-
cccctcgagaag gagatggcaaggaccaatc, respectively. The PCR
product was inserted into pcDNA4-mycHis with BamH I
and Xho I. The plasmid sequence was analyzed. The first
base pair after the adapter is identified as the transcription
start site of the human TMP21 gene.
Nuclear extraction and gel shift assay
To prepare NFAT-enriched nuclear extract, HEK293
cells were transiently transfected with pHA-NFAT1
expression plasmid for 48 hours. The cells were washed
with phosphate-buffered saline and harvested with five
volumes of buffer A [10 mM HEPES pH7.9, 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothrei-
tol (DTT), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF)]. After gentle pipeting the cells were incubated
on ice for 15 min. The cells were ruptured by 10 pestle
strokes in a Kontes all glass Dounce tissue grinder. 10%
NP40 was added to the homogenates on ice to a final
NP40 concentration of 0.5% for an additional 15 min
prior to 5 more strokes. Crude nuclei were collected by
centrifugation at 2 000 × g for 10 min. The nuclei were
washed three times with buffer A with 0.5% NP40 and
resuspended in buffer C [20 mM HEPES pH7.9, 0.4 M
NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol,
1 mM phenylmethylsulfonyl fluoride, 10% Glycerol] at
4°C for 15 min. The supernatant, which contains nuclear
proteins, was collected by centrifugation at 12 000 Xg
for 5 min at 4°C and stored -80°C.
Electrophoretic mobility shift assay (EMSA), also
known as gel shift assay (GSA), was performed as pre-
viously described [58]. Both sense and anti-sense NFAT
oligonucleotides, end-labeled with IRDye-680 (Li-COR),
were annealed to generate double-stranded probes. The
sequences for the sense strand probes were: consensus
NFAT (Wt-NFAT): 5’-gaggaaaatttg; NFAT mutant oli-
gonucleotides (Mt-NFAT): 5’-gaggaccctttg; TMP21-
NFAT-1: 5’-tatttccttttagtaattttccatc; TMP21- NFAT-2:
5’-ccctacttttccttgtatttgga; TMP21- NFAT-3: 5’-acct-
cggtttcctcatctgt; TMP21- NFAT-4: 5’-gatggaaatttaaag-
gaaacac; TMP21- NFAT-5: 5’-catttctaggaaaataact;
TMP21- NFAT-6: 5’-tctttctttccttctttcttt; TMP21- NFAT-
7: 5’-gaaatctttcctcgaaattttcctct; and TMP21- NFAT-8: 5’-
gtggctgtttcctattgggg. The end-labeled probes were incu-
bated with or without nuclear extract at 22°C in binding
buffer (100 mM Tris, 500 mM KCl, 10 mM DTT; pH
7.5)with 25 mM/L DTT, 2.5% Tween-20, and 1 μg poly
(dI-dC)/μl in 10 mM Tris and 1 mM EDTA (pH 7.5)
for 30 minutes, and the samples were analyzed on a 4%
nondenaturing polyacrylamide gel. For the competition
assays, the binding reaction was incubated with 10 pmol
(10 times) and 100 pmol (100 times) of unlabeled com-
petition oligonucleotides. For supershifting assay, the
polyclonal TMP21 antibody raised from rabbit [38] was
added to the EMSA reaction mixture.
Chromatin Immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously [61]
with modification. Cross-link between protein and chro-
matin was achieved by addition of formaldehyde to the
final concentration of 1.42% in NFAT-enriched HEK293
cells or SH-SY5Y cells for 15 min at room temperature
(22°C). Cross-link was quenched with glycine at final
concentration of 125 mM for 5 min at room
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temperature. Cells were then harvested in cold PBS and
lysed with IP buffer containing 150 mM NaCl, 50 mM
Tris-HCl (pH 7.5), 5 mM EDTA, NP-40 (0.5% vol/vol),
Triton X-100 (1.0% vol/vol), and 0.5 mM phenylmethyl-
sulfonyl fluoride (PMSF). The nuclear pellets were iso-
lated by centrifugation at 12,000g for 1 min, and
resuspended with the IP buffer. The chromatin was then
sheared by sonication on ice. For isolation of NFAT
binding complex, the chromatin solution was incubated
with NFAT antibody (Santa Cruz) or equal volume of
PBS overnight at 4°C. After immunoprecipitation, cross-
link was reversed by adding Chelex100 and boiling
beads for 10 min. The supernatant containing DNA
fragments was isolated by centrifugation at 12,000g for 1
min, which was then used as template for PCR analysis
of the chromatin fragment. “Primers” were used to
amplify NFAT putative consensus binding site (need to
confirm with Fang) located on the TMP21 promoter
region. Actin was used as internal control.
Quantitative RT-PCR
Total RNA was isolated from cells using TRI reagent
(Sigma). ThermoscripTM RT-PCR system (Invitrogen)
was used to synthesize the first strand cDNA using 5 μg of
total RNA as template following the manufacurer’s
instructions. The newly synthesized cDNA templates were
further amplified by Platinum Taq DNA polymerase (Invi-
trogen) in a 50 μl reaction. The human TMP21 gene spe-
cific primers 5’-cgggatccgccaccatgtctggtttgtctggcccac
forward, and 5’-ggaattcctcaatcaatttcttggccttg reverse, were
used to amplify a 660-bp fragment of the TMP21 coding
region. b-actin was used as an internal control. b-actin
gene-specific primers were: forword: 5’- cgaggatccggacttc-
gagcaagagatgg; reverse: 5’- cagtctagagaagcatttgcggtggacg.
All PCR products were analyzed on 1.5% agarose gels.
Immunoblotting
Cell lysates were resolved by 16% Tris-glycine sodium
dodecyl sulfate-polyacryamide gel electrophoresis and
immunblotting analysis was performed as described pre-
viously [38]. A rabbit anti-TMP21 polyclonal antibody
T21 raised against the TMP21 protein was used to
detect TMP21 expression [38]. Internal control b-actin
expression was analyzed with monoclonal anti-b-actin
antibody AC-15 (Sigma).
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